@article{3141318,
    title = "Chromosomal and proteome analysis of a new T24-based cell line model for
aggressive blamdder cancer",
    author = "Makridakis, Manousos and Gagos, Sarantis and Petrolekas, Andreas and and Roubelakis, Maria G. and Bitsika, Vasiliki and Stravodimos, Konstantinos and and Pavlakis, Kitty and Anagnou, Nicholas P. and Coleman, Jonathan and and Vlahou, Antonia",
    journal = "Cancer Genomics and Proteomics",
    year = "2009",
    volume = "9",
    number = "2",
    pages = "287-298",
    publisher = "Wiley",
    doi = "10.1002/pmic.200800121",
    keywords = "2-DE; Cytogenetic analysis; Metastatic variant; Proteomics; T24 cell
line",
    abstract = "Cell line models aid in understanding cancer aggressiveness. The aim of
this study was the establishment of a metastatic variant (T24M) of the
T24 bladder cancer cell line and its initial characterization at
chromosomal and proteomic levels. T24M were spontaneously developed in
mice from T24 cells, following cycles of subcutaneous injections and
culture in vitro. Transwell migration assays and injections in mice
revealed increased migration and tumorigenic properties of T24M compared
to the T24 cells. Cytogenetic analysis demonstrated that T24M retained
several karyotypic characteristics of the parental cells and also
acquired novel chromosomal aberrations related to aggressive bladder
cancer. Proteomic analysis of the T24 and T24M cells by 2-DE and MS led
to the generation of their 2-DE proteomic map and revealed differences
in multiple proteins. These include proteases of the lysosomal and
proteasome degradation pathways, mitochondrial and cytoskeletal
proteins. The 2-DE findings were confirmed by immunoblotting of cell
lysates and immunohistochemistry of bladder cancer tissue sections for
cathepsin D and activity assays for proteasome. Collectively, our
results suggest that the T24M cells reflect many known chromosomal and
proteomic aberrations encountered in aggressive bladder cancers but also
provide access to novel findings with potentially clinical applications."
}